Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”

This communication responds to the Letter to the Editor [1], where noticeably Messrs. Brian Hassett, Steven Vicik, and Brian Fitzpatrick from Pfizer Biotech contended that a particular glycan profile, presented in comparison to different profiles, does not correspond to the historical profile of the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research Vol. 2018; no. 2018; pp. 1 - 3
Main Authors: Flores-Ortiz, Luis F., Medina-Rivero, Emilio, Molina-Pérez, Aaron, Pérez, Néstor O., Ramírez-Ibanez, Nancy D., Salazar-Flores, Rodolfo D., Perdomo-Abúndez, Francisco C., López-Morales, Carlos A., Miranda-Hernández, Mariana P., Revilla-Beltri, Jorge
Format: Journal Article
Language:English
Published: Cairo, Egypt Hindawi Publishing Corporation 01-01-2018
Hindawi
Hindawi Limited
Subjects:
Antirheumatic Agents
Autoimmune Diseases
Biosimilar Pharmaceuticals
Chromatography
Etanercept
Humans
Immunology
Letter to the Editor
Mass spectrometry
Medical treatment
Scientific imaging
Mexico
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This communication responds to the Letter to the Editor [1], where noticeably Messrs. Brian Hassett, Steven Vicik, and Brian Fitzpatrick from Pfizer Biotech contended that a particular glycan profile, presented in comparison to different profiles, does not correspond to the historical profile of the reference medicinal product of etanercept (Enbrel®), as it is exposed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
Academic Editor: Ethan M. Shevach
ISSN:2314-8861
2314-7156
DOI:10.1155/2018/6156024